A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

A Massachusetts company is transforming the way breast cancer is detected in real time. Newton-based Lumicell launched its ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A fundamental shake-up of how we screen women for breast cancer could save more lives from the disease. Here are some options ...

Rather than pumping their mugs full of neurotoxins, wannabe glamour gals are using frozen bags of breast milk to achieve that forever-young firmness.

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...